Growth hormone peptides are compounds that stimulate the pituitary gland to release the body's own growth hormone. They are not human growth hormone (HGH). They are classified into two main types. The first group consists of growth hormone-releasing hormone analogues, including sermorelin. The second group comprises growth hormone-releasing peptides, such as ipamorelin. While promoted for muscle development, fat loss, and longevity, clinical evidence for these benefits remains limited. Among the compounds discussed, tesamorelin is the only peptide FDA-approved as a medical treatment, specifically indicated to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. Macimorelin is a nonpeptide secretagogue approved exclusively as a one-time diagnostic test for adult growth hormone deficiency. Other compounds lack robust clinical data, as human research remains small and primarily measures hormone levels instead of long-term health outcomes.
- What they are: Peptide compounds that stimulate the pituitary gland to release the body's own growth hormone (GH).
- FDA approval: Somatropin is approved for specific growth disorders and GH deficiency. Tesamorelin is approved for excess abdominal fat associated with HIV lipodystrophy; macimorelin is approved for diagnosing adult GH deficiency.
- Human evidence: Tesamorelin has clinical evidence for its approved indication. Evidence supporting lasting improvements from most other compounds remains limited.
- Known risks: Fluid retention, elevated IGF-1, joint symptoms, and impaired glucose regulation are reported concerns. Long-term safety remains uncertain.
- Compounding status (November 2026): GH-releasing peptides are not covered by the October 2026 HHS interim enforcement policy.
- Competitive sports: WADA's 2026 Prohibited List bans growth hormone-releasing factors (S2.2.4) in and out of competition.
What are growth hormone peptides?
Growth hormone peptides are compounds that influence the body's production and release of growth hormone (GH). The term is not a formally defined medical category but a marketing umbrella that includes several compounds with different structures and actions. For a general overview, see our peptide therapy basics.
GH regulation begins in the hypothalamus, a region of the brain that controls hormone signaling. The hypothalamus releases growth hormone-releasing hormone (GHRH), which signals the pituitary gland to produce and release GH. Once in circulation, GH acts on several tissues, including the liver, where it stimulates production of insulin-like growth factor 1 (IGF-1). IGF-1 mediates many of GH's effects on tissue growth, metabolism, and body composition.
GH secretion peaks during puberty and gradually declines throughout adulthood, largely because its release becomes less pronounced with age. In their 2025 review, Yuen et al. describe this age-related decline in GH secretion, commonly called somatopause, which does not automatically indicate growth hormone deficiency.1
The compounds marketed as growth hormone peptides fall into two groups:
- GHRH analogues: sermorelin, CJC-1295, and tesamorelin. They mimic GHRH's signaling activity.
- Growth hormone secretagogues acting on the ghrelin receptor: ipamorelin, GHRP-2, GHRP-6, and hexarelin, as well as MK-677 (ibutamoren), an oral nonpeptide compound that acts on the same receptor.
Although these compounds share an association with GH release, they are not interchangeable, and their clinical evidence differs considerably.
Growth hormone peptides vs. HGH: what is the difference?
Growth hormone peptides stimulate the pituitary gland to release the body's own growth hormone (GH), while human growth hormone (HGH) therapy supplies the hormone directly. Prescription HGH is usually somatropin, a laboratory-produced form of human GH that bypasses pituitary stimulation. Somatropin is approved to treat diagnosed GH deficiency in adults and specific growth-related conditions in children.
In the United States, federal law restricts HGH distribution to authorized medical uses under a physician's prescription. These restrictions help explain why GH-releasing peptides are marketed as alternatives: they stimulate the body's own GH production. However, this mechanism does not establish that they are safer or more natural, as adequate head-to-head clinical trials demonstrating superior safety or comparable long-term benefits over HGH are lacking.
Of all the GH-releasing peptides commonly marketed for wellness and body composition, tesamorelin is FDA-approved for one therapeutic use: reducing excess abdominal fat in adults with HIV-associated lipodystrophy.2 Macimorelin is not a peptide; it is an oral GH secretagogue approved as a single-dose diagnostic agent for adult GH deficiency, not as treatment.3
How do the main growth hormone peptides compare?
| Compound | Type | Administration | FDA status | Strongest human evidence |
|---|---|---|---|---|
| Sermorelin | GHRH analogue | Injections | Approved as Geref for diagnostic testing (~1990) and in 1997 to treat GH deficiency in children. Never approved for anti-aging, body composition, or general use in healthy adults. Discontinued by maker in 2008; FDA found in 2013 that it was not withdrawn for safety or effectiveness.4 | Older, small studies include a 16-week trial in 19 adults aged 55–71 using [Nle27]GHRH-(1–29)-NH₂, a modified GHRH analogue, not sermorelin itself.5 |
| CJC-1295 | Long-acting GHRH analogue | Injections | Not FDA-approved. In December 2024, FDA proposed against including five nominated CJC-1295 forms on the 503A Bulks List.6 | Two small, randomized, placebo-controlled ascending-dose trials of CJC-1295 with DAC, lasting 28 and 49 days, found sustained increases in GH and IGF-1 in healthy adults. A separate Phase II HIV-lipodystrophy trial was halted in 2006 after a participant died; cause and relationship to CJC-1295 not established.7 |
| Tesamorelin | GHRH analogue | Injections | Egrifta received FDA approval in 2010 to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. Indication remains specific to this population.8 | Two 26-week Phase III trials involving 412 and 404 adults with HIV-associated lipodystrophy found significant reductions in visceral abdominal fat. These trials supported its approval.9 |
| Ipamorelin | Ghrelin-receptor agonist (GHRP) | Injection (IV in the main trial) | Not approved. Advisers voted against it.10 | One Phase II randomized, placebo-controlled trial studied 114 patients after bowel-resection surgery. Ipamorelin did not significantly improve the primary endpoint, time to tolerance of a solid meal (p = 0.15).11 |
| MK-677 (ibutamoren) | Oral secretagogue (not a peptide) | Oral | Not approved. Advisers voted against it.12 | A two-year randomized trial in 65 adults aged 60–81 found increased fat-free mass, but no significant improvement in strength or physical function. Fasting glucose increased ~5 mg/dL; insulin sensitivity declined.13 |
Which growth hormone peptide is the best?
The best growth hormone peptide is the one supported by credible clinical evidence for a specific indication and outcome. However, as of November 2026, no head-to-head clinical trials have established that one growth hormone peptide is superior to another for muscle development, fat loss, recovery, or healthy aging.
The available evidence varies considerably between compounds. Tesamorelin, for example, has demonstrated reductions in visceral abdominal fat in adults with HIV-associated lipodystrophy. CJC-1295 has shown increases in GH and IGF-1 in small human trials, while MK-677 has increased fat-free mass in older adults without significant improvements in strength or physical function. As the comparison table shows, these findings support different conclusions about individual compounds but do not establish an overall winner.
Why are growth hormone peptides so popular?
Growth hormone peptides have attracted interest because their proposed effects overlap with several goals in the fitness and longevity markets: building muscle, reducing body fat, improving recovery, and maintaining physical performance with age. The decline in GH secretion during adulthood has also become a compelling marketing angle. Wellness marketers draw on this biological change to promote GH stimulation as a way to preserve youthful body composition, although, as Fernández-Garza and colleagues explain in their 2025 review of growth hormone and aging, declining GH levels with age do not necessarily indicate a deficiency or a need for treatment.14
Their popularity also has roots in bodybuilding and powerlifting, where growth hormone secretagogues have long attracted interest for their potential effects on body composition. Online peptide forums and social media have since helped extend these discussions into mainstream wellness and longevity communities. Growing consumer familiarity with injectable treatments, following the success of GLP-1 medications, has further helped broaden interest in other injectable compounds.
What does the research on growth hormone peptides actually show?
A measurable reduction in visceral fat is among the few clinical benefits demonstrated in trials of growth hormone secretagogues. In adults with HIV-associated lipodystrophy, tesamorelin produced this outcome; for most other compounds, human research has concentrated on hormonal changes, with considerably less evidence of meaningful improvements in physical function, body composition, or long-term health. No study has established that these agents extend lifespan.
Tesamorelin: The two pivotal Phase III trials reported by Falutz et al. (2007, 2010) involved adults with HIV-associated lipodystrophy. After 26 weeks, the first trial recorded a 27.8 cm² reduction in visceral adipose tissue with tesamorelin, compared with a 5.1 cm² increase with placebo. In the second, the reduction was 21 cm², compared with 1 cm² with placebo.15,16 These results supported FDA approval in 2010 for reducing excess abdominal fat in this specific population. They do not establish efficacy for general weight loss or anti-aging.
Sermorelin: Before its discontinuation, the branded formulation Geref had received FDA approval for two uses: assessing pituitary GH secretion in 1990 and treating idiopathic GH deficiency in children with growth failure in 1997. Its approvals were withdrawn in 2009 after the products were discontinued; the FDA determined that the withdrawal was not related to safety or effectiveness.2 Research in older adults offers less direct evidence. Khorram et al. (1997) studied a modified GHRH analogue in 19 adults aged 55–71. GH and IGF-1 increased in both sexes, but lean body mass increased significantly only in men. The analogue was not sermorelin acetate, so these findings cannot be attributed directly to sermorelin.5
CJC-1295: The hormonal response was striking in the trials published by Teichman et al. (2006). Among 66 healthy adults, GH increased two- to tenfold after a single injection, while IGF-1 rose 1.5- to threefold. With repeated administration, IGF-1 remained elevated for up to 28 days. The trials did not examine whether these changes improved strength, muscle growth, or physical performance.7 A separate Phase II trial in people with HIV-associated lipodystrophy was terminated after a participant died following a myocardial infarction. The FDA briefing describes the treating physician's report of coronary artery disease and plaque rupture; it does not establish that CJC-1295 caused the death.6
Ipamorelin: A hoped-for improvement in postoperative recovery did not translate into a statistically significant trial result. In a 2014 Phase II study, Beck et al. enrolled 117 adults undergoing bowel resection. Those receiving ipamorelin tolerated a solid meal sooner on average than the placebo group, but the difference (25.3 versus 32.6 hours) was not statistically significant. The primary endpoint was not met.11
MK-677 (ibutamoren): In a 2008 randomized trial, Nass et al. found that fat-free mass increased by 1.1 kg over 12 months in healthy older adults, compared with a 0.5 kg decrease with placebo. Muscle strength and physical function, however, did not significantly improve. Fasting glucose rose, and insulin sensitivity declined. MK-677 is an oral, nonpeptide GH secretagogue.13
Macimorelin: Garcia et al. (2018) studied this oral agent in 154 adults as a test for GH deficiency. Its diagnostic performance was comparable to that of the insulin tolerance test. Macimorelin is FDA-approved for a single-dose diagnostic assessment, not as treatment for GH deficiency.17
What are the side effects of growth hormone peptides, and are they safe?
The long-term safety of most growth hormone (GH) secretagogues has not been established in human studies. Available research has identified metabolic, cardiovascular, and fluid-retention effects, but the small study populations and limited follow-up make it difficult to determine the risks associated with prolonged use.
FDA-approved to reduce excess abdominal fat in adults with HIV-associated lipodystrophy, tesamorelin provides some of the clearest evidence of adverse effects. Its 2025 prescribing information reports joint pain, muscle pain, peripheral edema, and injection-site reactions. The FDA also reports that 5% of treated participants developed an HbA1c of at least 6.5% by week 26, compared with 1% receiving placebo. The prescribing information warns of glucose intolerance and fluid retention, while the long-term consequences of elevated IGF-1 remain uncertain.2
The FDA's December 2024 review of CJC-1295 identified increased heart rate and systemic vasodilatory reactions, alongside dizziness and hypotension. However, the available clinical studies were too limited to establish the safety of repeated exposure.6 In its October 2024 review of ipamorelin, the agency raised concerns about peptide aggregation and impurities that could trigger immune reactions. It also cited reports of serious adverse events, including deaths, in an intravenous study. These reports do not establish that ipamorelin caused the deaths.10
Evidence from MK-677 (ibutamoren), an oral nonpeptide GH secretagogue, adds to the metabolic concerns. In Nass et al.'s 2008 trial, increased appetite occurred in 67% of participants, compared with 36% receiving placebo. Participants also experienced transient lower-extremity edema and muscle pain. Fasting glucose increased ~5 mg/dL, while insulin sensitivity declined. A separate hip-fracture trial was terminated early following a potential congestive heart failure signal.13
For people obtaining these compounds outside approved medical channels, product quality introduces another safety concern. An online product labeled "research use only" is not verified for human administration, and its identity, purity, and sterility cannot be assumed. The FDA has specifically identified impurity and characterization concerns with certain peptides. Compounded drugs present a separate issue: they are not FDA-approved, and the agency does not review their safety, effectiveness, or quality before marketing.
Are growth hormone peptides FDA-approved or legal to compound?
The FDA has approved somatropin (human growth hormone, or HGH) for specified growth disorders in children and growth hormone deficiency in adults. Tesamorelin is approved to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. Macimorelin is approved for diagnosing adult growth hormone deficiency; it is not a treatment.
The FDA approved sermorelin as Geref in 1990 for diagnostic testing and in 1997 for treating idiopathic growth hormone deficiency in children with growth failure. Its manufacturer discontinued the product in 2008. In 2013, the FDA determined that Geref had not been withdrawn for reasons of safety or effectiveness. Some compounding pharmacies regard sermorelin as eligible for compounding because it was an ingredient in an FDA-approved drug. However, the FDA has not issued a sermorelin-specific statement confirming this interpretation.
What Section 503A allows
Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a bulk drug substance may qualify for compounding if it complies with an applicable USP or National Formulary monograph. If no such monograph exists, it must either be a component of an FDA-approved drug or appear on the FDA's 503A Bulks List. Additional requirements include a valid prescription for an identified patient, an FDA-registered manufacturing source, and a certificate of analysis. Being absent from the Bulks List does not, by itself, settle eligibility under the other statutory pathways. For the broader framework, see our peptide therapy guide.
In October 2024, the Pharmacy Compounding Advisory Committee voted against recommending ipamorelin and ibutamoren (MK-677) for the 503A Bulks List. In December 2024, it voted against recommending all five nominated forms of CJC-1295.
According to the FDA's posted interim category listings,18 as of November 2, 2026:
- CJC-1295: No current Category 1 or Category 2 designation; its 503A nominations were withdrawn.
- Ipamorelin acetate: No current 503A category; Category 2 under 503B.
- Ibutamoren (MK-677): Category 2 under both 503A and 503B.
On October 30, 2026, HHS published its interim enforcement-discretion policy for six peptide substances: BPC-157, epitalon, KPV, MOTS-c, semax and TB-500.19 CJC-1295, ipamorelin, and MK-677 are not included. The policy does not grant FDA approval or add substances to the 503A Bulks List.
A prescription, use of a compounding pharmacy, or a "research use only" label does not establish FDA approval or, by itself, make a product lawful to compound.
How are growth hormone peptides taken?
In clinical studies, most growth hormone peptides have been administered by subcutaneous injection, with the exception of MK-677 (ibutamoren), which is taken orally. The administration methods and dosing regimens studied were intended for specific medical conditions and cannot be assumed to apply to other uses. As a result, evidence-based doses and treatment schedules have not been established for uses beyond those studied.
Growth hormone peptides and competitive sports
The World Anti-Doping Code provides the international framework for anti-doping rules, adopted by signatories across major sports worldwide. The 2026 World Anti-Doping Agency (WADA) Prohibited List places growth hormone-releasing factors under S2.2.4, prohibiting them both in and out of competition. Named substances include GHRH analogues (CJC-1293, CJC-1295, sermorelin and tesamorelin); GH secretagogues (ibutamoren/MK-677, ipamorelin, and macimorelin); and GH-releasing peptides (GHRP-1 through GHRP-6, including hexarelin).20 Since professional leagues, other sporting organizations, and military testing programs may follow different prohibited-substance policies, athletes should check the rules applicable to their sport before using these compounds.
Questions to ask before considering growth hormone peptides
Before considering growth hormone peptides, individuals should discuss the following questions with their healthcare professional:
- What clinical evidence supports this compound for the intended purpose?
- Is it FDA-approved for this use, legally compounded, or sold as a research-use-only product?
- How can its quality, source, and manufacturing standards be verified?
- What are the potential risks, particularly in relation to existing health conditions or medications?
- What baseline tests and ongoing monitoring would be necessary, including IGF-1 and blood glucose?
- Are there approved treatments or better-supported alternatives for the intended goal?
- For competitive athletes, is the compound prohibited by their sport's governing body?
A registered dietitian's perspective on growth hormone peptides
I evaluate growth hormone peptides in the context of the nutritional and metabolic conditions required for tissue development. Growth hormone stimulates lipolysis and influences protein metabolism, but these effects do not guarantee muscle growth or favorable changes in body composition. Adequate energy availability, essential amino acid intake, and resistance exercise remain important determinants of muscle protein synthesis and tissue adaptation. Hormonal stimulation cannot compensate for inadequate nutritional support.
I also look closely at what reported changes in fat-free mass actually represent. Growth hormone can promote fluid retention, potentially contributing to increases in measured lean mass without corresponding gains in muscle strength or physical function. Equally important is its effect on glucose regulation: sustained GH elevation can reduce insulin sensitivity and impair glucose tolerance. These trade-offs matter when assessing claims of improved body composition or metabolic health. Ultimately, hormonal changes must be evaluated against functional outcomes and the longer-term metabolic consequences.
Frequently asked questions
Is HGH a peptide?
Human growth hormone (HGH), also called somatropin, is a protein hormone consisting of 191 amino acids. It is often called a peptide hormone because it is made of linked amino acids, but its size and structure classify it as a protein.21
How long do growth hormone peptides take to work?
There is no established timeline for meaningful health benefits from growth hormone peptides. Clinical studies have measured hormonal changes within days, while tesamorelin trials have demonstrated reductions in visceral fat over 26 weeks. These findings do not establish when other compounds might produce benefits or whether hormonal and body-composition changes improve physical function.
Are growth hormone peptides safe for women?
The safety of many growth hormone peptides in women remains insufficiently studied. Although some trials have included female participants, there is limited evidence to establish sex-specific responses and risks. Findings from studies of approved growth hormone treatments cannot automatically be applied to experimental or unapproved peptides.
Do growth hormone peptides cause cancer?
Growth hormone peptides have not been established as a cause of cancer in humans. However, growth hormone and insulin-like growth factor 1 (IGF-1) promote cell growth and proliferation, raising theoretical concerns about tumor development or progression. The long-term cancer risks associated with these compounds remain insufficiently studied.2
Does insurance cover growth hormone peptides?
In the United States, insurance may cover tesamorelin when prescribed for its approved indication: excess abdominal fat associated with HIV-related lipodystrophy. Coverage depends on the insurer and may require prior authorization. Unapproved peptides, including CJC-1295 and ipamorelin, are generally not covered for body-composition or performance-related uses.
References
- Yuen KCJ, et al. Physiology and Diseases of the Hypothalamic-Pituitary Axis in the Elderly. 2025. Available at: ncbi.nlm.nih.gov/books/NBK620038
- FDA. EGRIFTA WR Approved Label. 2025. Available at: accessdata.fda.gov
- MACRILEN (macimorelin acetate granule). Available at: dailymed.nlm.nih.gov
- FDA. 2013 GEREF Withdrawal Determination. Available at: federalregister.gov
- Khorram O, et al. 1997. Available at: pubmed.ncbi.nlm.nih.gov/9141536
- FDA. December 4, 2024 PCAC Meeting Transcript. Available at: fda.gov
- Teichman SL, et al. 2006. Available at: pubmed.ncbi.nlm.nih.gov/16352683
- FDA. Egrifta SV Prescribing Information. Available at: accessdata.fda.gov
- FDA. 2019 Egrifta Full Prescribing Information. Available at: accessdata.fda.gov
- FDA. October 29, 2024 PCAC Meeting Page. Available at: fda.gov
- Beck DE, et al. 2014. Available at: pubmed.ncbi.nlm.nih.gov/25331030
- FDA. October 29, 2024 PCAC Meeting Page. Available at: fda.gov
- Nass R, et al. 2008. Available at: pubmed.ncbi.nlm.nih.gov/18981485
- Fernández-Garza LE, et al. 2025. Available at: doi.org/10.3389/fragi.2025.1549453
- Falutz J, et al. 2007. Available at: pubmed.ncbi.nlm.nih.gov/18057338
- Falutz J, et al. 2010. Available at: pubmed.ncbi.nlm.nih.gov/20101189
- Garcia JM, et al. 2018. Available at: pubmed.ncbi.nlm.nih.gov/29860473
- FDA. Category 2 of Bulk Substances Nominated Under 503A/503B. Available at: fda.gov
- HHS 503A Peptide Enforcement Policy, Appendix B. Available at: federalregister.gov
- WADA. 2026 Prohibited List. Available at: wada-ama.org
- Brinkman JE, et al. Physiology, Growth Hormone. StatPearls. Available at: ncbi.nlm.nih.gov/books/NBK482141
This article is for informational and educational purposes only and does not constitute medical advice. It is not a substitute for diagnosis or treatment by a licensed healthcare provider. Always consult a qualified healthcare professional before starting, stopping, or adjusting any medication, peptide, or treatment.